Rational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse
• Cardiac donor–derived hepatitis C was cured with the use of a pangenotypic direct-acting antiviral agent, velpatasvir/sofosbuvir. • The treatement was effective against HCV genotype 3. • Sustained virologic response 12 weeks after therapy was achieved. • Antiviral therapy was safe despite initiati...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Gottlieb, Robert L. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017 |
|---|
| Umfang: |
3 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Investigating polyethersulfone interleaved Glass/Carbon hybrid composite under impact and its comparison with GLARE - Fotouhi, Sakineh ELSEVIER, 2019, official journal of the Heart Failure Society of America and the Japanese Heart Failure Society, New York, NY |
|---|---|
| Übergeordnetes Werk: |
volume:23 ; year:2017 ; number:10 ; pages:765-767 ; extent:3 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.cardfail.2017.08.448 |
|---|
| Katalog-ID: |
ELV025516574 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV025516574 | ||
| 003 | DE-627 | ||
| 005 | 20230623181002.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cardfail.2017.08.448 |2 doi | |
| 028 | 5 | 2 | |a GBVA2017017000029.pica |
| 035 | |a (DE-627)ELV025516574 | ||
| 035 | |a (ELSEVIER)S1071-9164(17)31124-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 670 |q VZ |
| 084 | |a 51.75 |2 bkl | ||
| 100 | 1 | |a Gottlieb, Robert L. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse |
| 264 | 1 | |c 2017 | |
| 300 | |a 3 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Cardiac donor–derived hepatitis C was cured with the use of a pangenotypic direct-acting antiviral agent, velpatasvir/sofosbuvir. • The treatement was effective against HCV genotype 3. • Sustained virologic response 12 weeks after therapy was achieved. • Antiviral therapy was safe despite initiation while the patient was intensely immunosuppressed just 2 weeks after transplant. • Cardiac donor shortage addressed by this therapy is limited by pharmacoeconomics. | ||
| 700 | 1 | |a Sam, Teena |4 oth | |
| 700 | 1 | |a Wada, Suzanne Y. |4 oth | |
| 700 | 1 | |a Trotter, James F. |4 oth | |
| 700 | 1 | |a Asrani, Sumeet K. |4 oth | |
| 700 | 1 | |a Lima, Brian |4 oth | |
| 700 | 1 | |a Joseph, Susan M. |4 oth | |
| 700 | 1 | |a Gonzalez-Stawinski, Gonzalo V. |4 oth | |
| 700 | 1 | |a Hall, Shelley A. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Fotouhi, Sakineh ELSEVIER |t Investigating polyethersulfone interleaved Glass/Carbon hybrid composite under impact and its comparison with GLARE |d 2019 |d official journal of the Heart Failure Society of America and the Japanese Heart Failure Society |g New York, NY |w (DE-627)ELV002771764 |
| 773 | 1 | 8 | |g volume:23 |g year:2017 |g number:10 |g pages:765-767 |g extent:3 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.cardfail.2017.08.448 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 51.75 |j Verbundwerkstoffe |j Schichtstoffe |q VZ |
| 951 | |a AR | ||
| 952 | |d 23 |j 2017 |e 10 |h 765-767 |g 3 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
r l g rl rlg |
|---|---|
| matchkey_str |
gottliebrobertlsamteenawadasuzanneytrott:2017----:ainlertaslnfoaeaiicoonwniiawao |
| hierarchy_sort_str |
2017 |
| bklnumber |
51.75 |
| publishDate |
2017 |
| allfields |
10.1016/j.cardfail.2017.08.448 doi GBVA2017017000029.pica (DE-627)ELV025516574 (ELSEVIER)S1071-9164(17)31124-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 670 VZ 51.75 bkl Gottlieb, Robert L. verfasserin aut Rational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse 2017 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Cardiac donor–derived hepatitis C was cured with the use of a pangenotypic direct-acting antiviral agent, velpatasvir/sofosbuvir. • The treatement was effective against HCV genotype 3. • Sustained virologic response 12 weeks after therapy was achieved. • Antiviral therapy was safe despite initiation while the patient was intensely immunosuppressed just 2 weeks after transplant. • Cardiac donor shortage addressed by this therapy is limited by pharmacoeconomics. Sam, Teena oth Wada, Suzanne Y. oth Trotter, James F. oth Asrani, Sumeet K. oth Lima, Brian oth Joseph, Susan M. oth Gonzalez-Stawinski, Gonzalo V. oth Hall, Shelley A. oth Enthalten in Elsevier Fotouhi, Sakineh ELSEVIER Investigating polyethersulfone interleaved Glass/Carbon hybrid composite under impact and its comparison with GLARE 2019 official journal of the Heart Failure Society of America and the Japanese Heart Failure Society New York, NY (DE-627)ELV002771764 volume:23 year:2017 number:10 pages:765-767 extent:3 https://doi.org/10.1016/j.cardfail.2017.08.448 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.75 Verbundwerkstoffe Schichtstoffe VZ AR 23 2017 10 765-767 3 045F 610 |
| spelling |
10.1016/j.cardfail.2017.08.448 doi GBVA2017017000029.pica (DE-627)ELV025516574 (ELSEVIER)S1071-9164(17)31124-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 670 VZ 51.75 bkl Gottlieb, Robert L. verfasserin aut Rational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse 2017 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Cardiac donor–derived hepatitis C was cured with the use of a pangenotypic direct-acting antiviral agent, velpatasvir/sofosbuvir. • The treatement was effective against HCV genotype 3. • Sustained virologic response 12 weeks after therapy was achieved. • Antiviral therapy was safe despite initiation while the patient was intensely immunosuppressed just 2 weeks after transplant. • Cardiac donor shortage addressed by this therapy is limited by pharmacoeconomics. Sam, Teena oth Wada, Suzanne Y. oth Trotter, James F. oth Asrani, Sumeet K. oth Lima, Brian oth Joseph, Susan M. oth Gonzalez-Stawinski, Gonzalo V. oth Hall, Shelley A. oth Enthalten in Elsevier Fotouhi, Sakineh ELSEVIER Investigating polyethersulfone interleaved Glass/Carbon hybrid composite under impact and its comparison with GLARE 2019 official journal of the Heart Failure Society of America and the Japanese Heart Failure Society New York, NY (DE-627)ELV002771764 volume:23 year:2017 number:10 pages:765-767 extent:3 https://doi.org/10.1016/j.cardfail.2017.08.448 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.75 Verbundwerkstoffe Schichtstoffe VZ AR 23 2017 10 765-767 3 045F 610 |
| allfields_unstemmed |
10.1016/j.cardfail.2017.08.448 doi GBVA2017017000029.pica (DE-627)ELV025516574 (ELSEVIER)S1071-9164(17)31124-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 670 VZ 51.75 bkl Gottlieb, Robert L. verfasserin aut Rational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse 2017 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Cardiac donor–derived hepatitis C was cured with the use of a pangenotypic direct-acting antiviral agent, velpatasvir/sofosbuvir. • The treatement was effective against HCV genotype 3. • Sustained virologic response 12 weeks after therapy was achieved. • Antiviral therapy was safe despite initiation while the patient was intensely immunosuppressed just 2 weeks after transplant. • Cardiac donor shortage addressed by this therapy is limited by pharmacoeconomics. Sam, Teena oth Wada, Suzanne Y. oth Trotter, James F. oth Asrani, Sumeet K. oth Lima, Brian oth Joseph, Susan M. oth Gonzalez-Stawinski, Gonzalo V. oth Hall, Shelley A. oth Enthalten in Elsevier Fotouhi, Sakineh ELSEVIER Investigating polyethersulfone interleaved Glass/Carbon hybrid composite under impact and its comparison with GLARE 2019 official journal of the Heart Failure Society of America and the Japanese Heart Failure Society New York, NY (DE-627)ELV002771764 volume:23 year:2017 number:10 pages:765-767 extent:3 https://doi.org/10.1016/j.cardfail.2017.08.448 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.75 Verbundwerkstoffe Schichtstoffe VZ AR 23 2017 10 765-767 3 045F 610 |
| allfieldsGer |
10.1016/j.cardfail.2017.08.448 doi GBVA2017017000029.pica (DE-627)ELV025516574 (ELSEVIER)S1071-9164(17)31124-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 670 VZ 51.75 bkl Gottlieb, Robert L. verfasserin aut Rational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse 2017 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Cardiac donor–derived hepatitis C was cured with the use of a pangenotypic direct-acting antiviral agent, velpatasvir/sofosbuvir. • The treatement was effective against HCV genotype 3. • Sustained virologic response 12 weeks after therapy was achieved. • Antiviral therapy was safe despite initiation while the patient was intensely immunosuppressed just 2 weeks after transplant. • Cardiac donor shortage addressed by this therapy is limited by pharmacoeconomics. Sam, Teena oth Wada, Suzanne Y. oth Trotter, James F. oth Asrani, Sumeet K. oth Lima, Brian oth Joseph, Susan M. oth Gonzalez-Stawinski, Gonzalo V. oth Hall, Shelley A. oth Enthalten in Elsevier Fotouhi, Sakineh ELSEVIER Investigating polyethersulfone interleaved Glass/Carbon hybrid composite under impact and its comparison with GLARE 2019 official journal of the Heart Failure Society of America and the Japanese Heart Failure Society New York, NY (DE-627)ELV002771764 volume:23 year:2017 number:10 pages:765-767 extent:3 https://doi.org/10.1016/j.cardfail.2017.08.448 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.75 Verbundwerkstoffe Schichtstoffe VZ AR 23 2017 10 765-767 3 045F 610 |
| allfieldsSound |
10.1016/j.cardfail.2017.08.448 doi GBVA2017017000029.pica (DE-627)ELV025516574 (ELSEVIER)S1071-9164(17)31124-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 670 VZ 51.75 bkl Gottlieb, Robert L. verfasserin aut Rational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse 2017 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Cardiac donor–derived hepatitis C was cured with the use of a pangenotypic direct-acting antiviral agent, velpatasvir/sofosbuvir. • The treatement was effective against HCV genotype 3. • Sustained virologic response 12 weeks after therapy was achieved. • Antiviral therapy was safe despite initiation while the patient was intensely immunosuppressed just 2 weeks after transplant. • Cardiac donor shortage addressed by this therapy is limited by pharmacoeconomics. Sam, Teena oth Wada, Suzanne Y. oth Trotter, James F. oth Asrani, Sumeet K. oth Lima, Brian oth Joseph, Susan M. oth Gonzalez-Stawinski, Gonzalo V. oth Hall, Shelley A. oth Enthalten in Elsevier Fotouhi, Sakineh ELSEVIER Investigating polyethersulfone interleaved Glass/Carbon hybrid composite under impact and its comparison with GLARE 2019 official journal of the Heart Failure Society of America and the Japanese Heart Failure Society New York, NY (DE-627)ELV002771764 volume:23 year:2017 number:10 pages:765-767 extent:3 https://doi.org/10.1016/j.cardfail.2017.08.448 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.75 Verbundwerkstoffe Schichtstoffe VZ AR 23 2017 10 765-767 3 045F 610 |
| language |
English |
| source |
Enthalten in Investigating polyethersulfone interleaved Glass/Carbon hybrid composite under impact and its comparison with GLARE New York, NY volume:23 year:2017 number:10 pages:765-767 extent:3 |
| sourceStr |
Enthalten in Investigating polyethersulfone interleaved Glass/Carbon hybrid composite under impact and its comparison with GLARE New York, NY volume:23 year:2017 number:10 pages:765-767 extent:3 |
| format_phy_str_mv |
Article |
| bklname |
Verbundwerkstoffe Schichtstoffe |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Investigating polyethersulfone interleaved Glass/Carbon hybrid composite under impact and its comparison with GLARE |
| authorswithroles_txt_mv |
Gottlieb, Robert L. @@aut@@ Sam, Teena @@oth@@ Wada, Suzanne Y. @@oth@@ Trotter, James F. @@oth@@ Asrani, Sumeet K. @@oth@@ Lima, Brian @@oth@@ Joseph, Susan M. @@oth@@ Gonzalez-Stawinski, Gonzalo V. @@oth@@ Hall, Shelley A. @@oth@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV002771764 |
| dewey-sort |
3610 |
| id |
ELV025516574 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV025516574</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623181002.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.cardfail.2017.08.448</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017017000029.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV025516574</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1071-9164(17)31124-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">670</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.75</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Gottlieb, Robert L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Rational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">3</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Cardiac donor–derived hepatitis C was cured with the use of a pangenotypic direct-acting antiviral agent, velpatasvir/sofosbuvir. • The treatement was effective against HCV genotype 3. • Sustained virologic response 12 weeks after therapy was achieved. • Antiviral therapy was safe despite initiation while the patient was intensely immunosuppressed just 2 weeks after transplant. • Cardiac donor shortage addressed by this therapy is limited by pharmacoeconomics.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sam, Teena</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wada, Suzanne Y.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Trotter, James F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Asrani, Sumeet K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lima, Brian</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Joseph, Susan M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gonzalez-Stawinski, Gonzalo V.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hall, Shelley A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Fotouhi, Sakineh ELSEVIER</subfield><subfield code="t">Investigating polyethersulfone interleaved Glass/Carbon hybrid composite under impact and its comparison with GLARE</subfield><subfield code="d">2019</subfield><subfield code="d">official journal of the Heart Failure Society of America and the Japanese Heart Failure Society</subfield><subfield code="g">New York, NY</subfield><subfield code="w">(DE-627)ELV002771764</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:10</subfield><subfield code="g">pages:765-767</subfield><subfield code="g">extent:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.cardfail.2017.08.448</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.75</subfield><subfield code="j">Verbundwerkstoffe</subfield><subfield code="j">Schichtstoffe</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2017</subfield><subfield code="e">10</subfield><subfield code="h">765-767</subfield><subfield code="g">3</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Gottlieb, Robert L. |
| spellingShingle |
Gottlieb, Robert L. ddc 610 ddc 670 bkl 51.75 Rational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse |
| authorStr |
Gottlieb, Robert L. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV002771764 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 670 - Manufacturing |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 670 VZ 51.75 bkl Rational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse |
| topic |
ddc 610 ddc 670 bkl 51.75 |
| topic_unstemmed |
ddc 610 ddc 670 bkl 51.75 |
| topic_browse |
ddc 610 ddc 670 bkl 51.75 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
t s ts s y w sy syw j f t jf jft s k a sk ska b l bl s m j sm smj g v g s gvg gvgs s a h sa sah |
| hierarchy_parent_title |
Investigating polyethersulfone interleaved Glass/Carbon hybrid composite under impact and its comparison with GLARE |
| hierarchy_parent_id |
ELV002771764 |
| dewey-tens |
610 - Medicine & health 670 - Manufacturing |
| hierarchy_top_title |
Investigating polyethersulfone interleaved Glass/Carbon hybrid composite under impact and its comparison with GLARE |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV002771764 |
| title |
Rational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse |
| ctrlnum |
(DE-627)ELV025516574 (ELSEVIER)S1071-9164(17)31124-7 |
| title_full |
Rational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse |
| author_sort |
Gottlieb, Robert L. |
| journal |
Investigating polyethersulfone interleaved Glass/Carbon hybrid composite under impact and its comparison with GLARE |
| journalStr |
Investigating polyethersulfone interleaved Glass/Carbon hybrid composite under impact and its comparison with GLARE |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
765 |
| author_browse |
Gottlieb, Robert L. |
| container_volume |
23 |
| physical |
3 |
| class |
610 610 DE-600 670 VZ 51.75 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Gottlieb, Robert L. |
| doi_str_mv |
10.1016/j.cardfail.2017.08.448 |
| dewey-full |
610 670 |
| title_sort |
rational heart transplant from a hepatitis c donor: new antiviral weapons conquer the trojan horse |
| title_auth |
Rational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse |
| abstract |
• Cardiac donor–derived hepatitis C was cured with the use of a pangenotypic direct-acting antiviral agent, velpatasvir/sofosbuvir. • The treatement was effective against HCV genotype 3. • Sustained virologic response 12 weeks after therapy was achieved. • Antiviral therapy was safe despite initiation while the patient was intensely immunosuppressed just 2 weeks after transplant. • Cardiac donor shortage addressed by this therapy is limited by pharmacoeconomics. |
| abstractGer |
• Cardiac donor–derived hepatitis C was cured with the use of a pangenotypic direct-acting antiviral agent, velpatasvir/sofosbuvir. • The treatement was effective against HCV genotype 3. • Sustained virologic response 12 weeks after therapy was achieved. • Antiviral therapy was safe despite initiation while the patient was intensely immunosuppressed just 2 weeks after transplant. • Cardiac donor shortage addressed by this therapy is limited by pharmacoeconomics. |
| abstract_unstemmed |
• Cardiac donor–derived hepatitis C was cured with the use of a pangenotypic direct-acting antiviral agent, velpatasvir/sofosbuvir. • The treatement was effective against HCV genotype 3. • Sustained virologic response 12 weeks after therapy was achieved. • Antiviral therapy was safe despite initiation while the patient was intensely immunosuppressed just 2 weeks after transplant. • Cardiac donor shortage addressed by this therapy is limited by pharmacoeconomics. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| container_issue |
10 |
| title_short |
Rational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse |
| url |
https://doi.org/10.1016/j.cardfail.2017.08.448 |
| remote_bool |
true |
| author2 |
Sam, Teena Wada, Suzanne Y. Trotter, James F. Asrani, Sumeet K. Lima, Brian Joseph, Susan M. Gonzalez-Stawinski, Gonzalo V. Hall, Shelley A. |
| author2Str |
Sam, Teena Wada, Suzanne Y. Trotter, James F. Asrani, Sumeet K. Lima, Brian Joseph, Susan M. Gonzalez-Stawinski, Gonzalo V. Hall, Shelley A. |
| ppnlink |
ELV002771764 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.cardfail.2017.08.448 |
| up_date |
2024-07-06T17:45:41.108Z |
| _version_ |
1803852648137359360 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV025516574</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623181002.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.cardfail.2017.08.448</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017017000029.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV025516574</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1071-9164(17)31124-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">670</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.75</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Gottlieb, Robert L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Rational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">3</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Cardiac donor–derived hepatitis C was cured with the use of a pangenotypic direct-acting antiviral agent, velpatasvir/sofosbuvir. • The treatement was effective against HCV genotype 3. • Sustained virologic response 12 weeks after therapy was achieved. • Antiviral therapy was safe despite initiation while the patient was intensely immunosuppressed just 2 weeks after transplant. • Cardiac donor shortage addressed by this therapy is limited by pharmacoeconomics.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sam, Teena</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wada, Suzanne Y.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Trotter, James F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Asrani, Sumeet K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lima, Brian</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Joseph, Susan M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gonzalez-Stawinski, Gonzalo V.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hall, Shelley A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Fotouhi, Sakineh ELSEVIER</subfield><subfield code="t">Investigating polyethersulfone interleaved Glass/Carbon hybrid composite under impact and its comparison with GLARE</subfield><subfield code="d">2019</subfield><subfield code="d">official journal of the Heart Failure Society of America and the Japanese Heart Failure Society</subfield><subfield code="g">New York, NY</subfield><subfield code="w">(DE-627)ELV002771764</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:10</subfield><subfield code="g">pages:765-767</subfield><subfield code="g">extent:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.cardfail.2017.08.448</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.75</subfield><subfield code="j">Verbundwerkstoffe</subfield><subfield code="j">Schichtstoffe</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2017</subfield><subfield code="e">10</subfield><subfield code="h">765-767</subfield><subfield code="g">3</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4019012 |